CHP
MACK

Cable Hill Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cable Hill Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-318
Closed -$3K – 1019
2017
Q4 		$3K Buy
+318
New +$2.96K ﹤0.01% 843

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cable Hill Partners's MACK Position: Q1 2018 in Review

Cable Hill Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2018, closing a stake of 318 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in MACK in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

  • Cable Hill Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 318 Merrimack Pharmaceuticals, Inc. shares in Q1 2018, an estimated $3K.
  • Cable Hill Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's Merrimack Pharmaceuticals, Inc. position peaked at $3K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.